Editing Leukemia (section)

===Hairy cell===
{{Further|Hairy cell leukemia#Treatment}}

'''Decision to treat'''<br />
People with hairy cell leukemia who are symptom-free typically do not receive immediate treatment. Treatment is generally considered necessary when the person shows signs and symptoms such as low blood cell counts (e.g., infection-fighting neutrophil count below 1.0&nbsp;K/μL), frequent infections, unexplained bruises, anemia, or fatigue that is significant enough to disrupt the person's everyday life.<ref>{{cite web |url=https://www.lecturio.com/concepts/hairy-cell-leukemia/| title=Hairy Cell Leukemia
|website=The Lecturio Medical Concept Library |access-date= 24 July 2021}}</ref>

'''Typical treatment approach'''<br />
People who need treatment usually receive either one week of [[cladribine]], given daily by intravenous infusion or a simple injection under the skin, or six months of [[pentostatin]], given every four weeks by intravenous infusion. In most cases, one round of treatment will produce a prolonged remission.<ref>{{cite journal | vauthors = Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J, Wiater E, Zdunczyk A, Dybowicz J, Dmoszynska A, Wojtaszko M, Zdziarska B, Calbecka M, Kostyra A, Hellmann A, Lewandowski K, Stella-Holowiecka B, Sulek K, Gawronski K, Skotnicki AB, Nowak W, Zawilska K, Molendowicz-Portala L, Kloczko J, Sokolowski J, Warzocha K, Seferynska I, Ceglarek B, Konopka L | title = Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial | journal = Blood | volume = 109 | issue = 9 | pages = 3672–5 | date = May 2007 | pmid = 17209059 | doi = 10.1182/blood-2006-08-042929 | doi-access = free }}</ref>

Other treatments include [[rituximab]] infusion or self-injection with [[Interferon-alpha]]. In limited cases, the person may benefit from ''[[splenectomy]]'' (removal of the [[spleen]]). These treatments are not typically given as the first treatment because their success rates are lower than cladribine or pentostatin.<ref>{{cite journal | vauthors = Saven A, Burian C, Adusumalli J, Koziol JA | title = Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia | journal = Blood | volume = 93 | issue = 8 | pages = 2471–7 | date = April 1999 | pmid = 10194424 | doi = 10.1182/blood.V93.8.2471 }}</ref>